Purchase this article with an account.
S. Sivaprasad, A. Saeed, S. Beatty, J. L. Olea, S. Grisanti, C. Rosina, G. Staurenghi, P. Hykin; Intravitreal Pegaptanib Sodium for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration- A Pan-European Experience. Invest. Ophthalmol. Vis. Sci. 2008;49(13):335.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The phase III studies of pegaptanib sodium [VEGF Inhibition Study in Ocular Neovascularization trials (VISION)] showed that 6 weekly pegaptanib sodium when given as intravitreous injections to patients with subfoveal choroidal neovascularization secondary to ARMD stabilised vision (loss of less than 15 letters ETDRS) in 70% . Gain of vision (gain of ≥15 letters ETDRS) was noted in 6%. This aim of this audit is to compare the visual outcome obtained in real-life experience with pegaptanib sodium with that of the VISION study.
A combined cohort of 164 patients from 5 different European countries was included. Consecutive patients with any angiographic subtype of subfoveal choroidal neovascularization secondary to AMD and best-corrected visual acuities (BCVA) in the study eye of 20/40 to 20/320 that received 0.3mg pegaptanib sodium as the first-line treatment were included. After 3 doses of six-weekly pegaptanib sodium, a PRN dosing schedule was followed. The final follow-up is 24 weeks.
The mean baseline visual acuity was 43.3 ETDRS letters and the mean baseline lesion size was 3664 um. 90.2% stabilised vision and 14.6% gained more than 15 letters. The average change in visual acuity for all lesions was a loss of 1.7 letters. Lesion subtypes and baseline lesion size did not influence the final visual outcome.
The visual acuity outcome with Pegaptanib sodium was better than the VISION study despite a PRN dosing schedule.
This PDF is available to Subscribers Only